Core Insights - Co-Diagnostics, Inc. has conducted an in silico analysis confirming the effectiveness of its Co-Primers®-based PCR tests for detecting chikungunya virus (CHIKV), demonstrating high homology with over 1,200 CHIKV sequences and confirming reactivity against recent strains [1][4]. Company Developments - The Co-Diagnostics Logix Smart® ZDC Test received CE-marking regulatory clearance in 2019, allowing it to be sold as an in vitro diagnostic for Zika, dengue, and chikungunya, utilizing the patented Co-Primers technology [4]. - Co-Diagnostics has a joint venture in India, CoSara Diagnostics Pvt Ltd, which received clearance in October 2021 to manufacture and sell a multiplex RT-PCR test for dengue and chikungunya, also based on the Co-Primers platform [7]. Industry Context - As of July 2025, there have been nearly 250,000 cases and 90 deaths from CHIKV globally, with significant concentrations in South America and an estimated 5.6 billion people living in at-risk areas across 119 countries due to climate change affecting mosquito habitats [2]. - Chikungunya poses a considerable economic burden, particularly in low- and middle-income countries, with long-term health consequences such as chronic arthritis affecting 40% of patients [3].